Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030040 | 0.87 | MEN1 (0.41) | THRBMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL4770737 | 0.84 | THRB (0.39) | THRBMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL4572769 | 0.77 | THRB (0.40) | THRBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL9772233 | 0.77 | ALOX15 (0.33) | MEN1CYP1A2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17030089 | 0.76 | — | — | |
| SCHEMBL4631299 | 0.76 | — | — | |
| SCHEMBL17030142 | 0.76 | TSHR (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL17022784 | 0.74 | LMNA (0.36) | THRBALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL27882889 | 0.74 | LMNA (0.36) | THRBALDH1A1LMNA | |
| SCHEMBL1025215 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3284482-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2018-02-21 | — | — | EP | disclosed |
| US-20150250217-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | NISSAN FOODS HOLDINGS CO., LTD. (JP) | 2015-09-10 | — | — | US | disclosed |
| EP-2910130-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | Nissin Foods Holdings Co., Ltd. (JP) | 2015-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250217-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | TAS2R8, TAS2R13, TAS2R38 | THRB 960/4885MEN1 957/4885CYP1A2 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.